JOP20190056B1 - مركبات للاستخدام في علاج القصور الكلوي الحاد - Google Patents

مركبات للاستخدام في علاج القصور الكلوي الحاد

Info

Publication number
JOP20190056B1
JOP20190056B1 JOP/2019/0056A JOP20190056A JOP20190056B1 JO P20190056 B1 JOP20190056 B1 JO P20190056B1 JO P20190056 A JOP20190056 A JO P20190056A JO P20190056 B1 JOP20190056 B1 JO P20190056B1
Authority
JO
Jordan
Prior art keywords
compounds
treatment
acute renal
renal impairment
impairment
Prior art date
Application number
JOP/2019/0056A
Other languages
Arabic (ar)
English (en)
Inventor
Scott Trzaska
Bharat Lagu
Michael Patane
Effie Tozzo
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of JOP20190056A1 publication Critical patent/JOP20190056A1/ar
Application granted granted Critical
Publication of JOP20190056B1 publication Critical patent/JOP20190056B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JOP/2019/0056A 2016-10-05 2017-10-05 مركبات للاستخدام في علاج القصور الكلوي الحاد JOP20190056B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (2)

Publication Number Publication Date
JOP20190056A1 JOP20190056A1 (ar) 2019-03-24
JOP20190056B1 true JOP20190056B1 (ar) 2022-03-14

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0056A JOP20190056B1 (ar) 2016-10-05 2017-10-05 مركبات للاستخدام في علاج القصور الكلوي الحاد

Country Status (33)

Country Link
US (1) US20210283116A1 (enExample)
EP (1) EP3522880B1 (enExample)
JP (1) JP7065839B2 (enExample)
KR (1) KR20190062502A (enExample)
CN (1) CN109789117B (enExample)
AU (1) AU2017340760B2 (enExample)
BR (1) BR112019005539A2 (enExample)
CA (1) CA3036723A1 (enExample)
CO (1) CO2019004561A2 (enExample)
CY (1) CY1124759T1 (enExample)
DK (1) DK3522880T3 (enExample)
ES (1) ES2859487T3 (enExample)
HR (1) HRP20210294T1 (enExample)
HU (1) HUE053557T2 (enExample)
IL (1) IL265749A (enExample)
JO (1) JOP20190056B1 (enExample)
LT (1) LT3522880T (enExample)
MA (1) MA46459B1 (enExample)
MD (1) MD3522880T2 (enExample)
MX (1) MX387518B (enExample)
MY (1) MY192385A (enExample)
PH (1) PH12019500725A1 (enExample)
PL (1) PL3522880T3 (enExample)
PT (1) PT3522880T (enExample)
RS (1) RS61573B1 (enExample)
RU (1) RU2753607C2 (enExample)
SG (1) SG11201901925RA (enExample)
SI (1) SI3522880T1 (enExample)
SM (1) SMT202100111T1 (enExample)
TW (1) TWI778982B (enExample)
UA (1) UA124019C2 (enExample)
WO (1) WO2018067857A1 (enExample)
ZA (1) ZA201901743B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2949852T3 (es) 2015-10-07 2023-10-03 Mitobridge Inc Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos
BR112018069930B1 (pt) * 2016-04-13 2024-02-20 Mitobridge, Inc Compostos agonistas de ppar, uso dos mesmos e composição farmacêutica
MA46460A (fr) * 2016-10-05 2021-03-17 Mitobridge Inc Formes cristallines et salines de composés agonistes de ppar
KR20220042150A (ko) * 2019-07-19 2022-04-04 비포르 (인터내셔날) 아게 신장 손상의 예방 및 치료에의 용도를 위한 페로포틴 억제제
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20240019753A (ko) * 2021-03-08 2024-02-14 아비오닉스 파마 에스에이 간 질환을 치료하는 데 유용한 화합물
CN115813901B (zh) * 2022-10-20 2024-10-22 南京市儿童医院 3-苯基戊二酸衍生物类小分子在制备防治顺铂诱导的急性肾损伤药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009119B1 (ru) * 2003-09-19 2007-10-26 Янссен Фармацевтика Н. В. 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
CN102209532B (zh) * 2008-10-17 2015-07-22 西玛贝治疗公司 减少小而致密的ldl颗粒的方法
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
CN105324395A (zh) * 2013-03-08 2016-02-10 艾伯维公司 治疗急性肾损伤的方法
AU2014247953A1 (en) * 2013-04-05 2015-11-12 Mitobridge, Inc. PPAR agonists
EP2862574A1 (en) * 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
US10300108B2 (en) * 2013-12-03 2019-05-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
ES2949852T3 (es) * 2015-10-07 2023-10-03 Mitobridge Inc Agonistas de PPAR, compuestos, composiciones farmacéuticas y métodos de uso de los mismos

Also Published As

Publication number Publication date
HRP20210294T1 (hr) 2021-04-16
CO2019004561A2 (es) 2019-07-31
AU2017340760B2 (en) 2023-07-27
RU2019111421A3 (enExample) 2021-02-05
MX2019003949A (es) 2019-06-10
CY1124759T1 (el) 2022-07-22
TWI778982B (zh) 2022-10-01
BR112019005539A2 (pt) 2019-06-18
US20210283116A1 (en) 2021-09-16
MY192385A (en) 2022-08-18
MA46459A (fr) 2019-08-14
PH12019500725A1 (en) 2019-08-05
UA124019C2 (uk) 2021-07-07
KR20190062502A (ko) 2019-06-05
ZA201901743B (en) 2022-04-28
JP2019533660A (ja) 2019-11-21
JOP20190056A1 (ar) 2019-03-24
MA46459B1 (fr) 2021-03-31
MD3522880T2 (ro) 2021-03-31
SMT202100111T1 (it) 2021-05-07
HUE053557T2 (hu) 2021-07-28
RS61573B1 (sr) 2021-04-29
EP3522880A1 (en) 2019-08-14
JP7065839B2 (ja) 2022-05-12
LT3522880T (lt) 2021-03-25
SI3522880T1 (sl) 2021-07-30
CN109789117B (zh) 2022-08-23
IL265749A (en) 2019-06-30
MX387518B (es) 2025-03-18
AU2017340760A1 (en) 2019-03-21
CN109789117A (zh) 2019-05-21
DK3522880T3 (en) 2021-01-18
TW201815391A (zh) 2018-05-01
CA3036723A1 (en) 2018-04-12
SG11201901925RA (en) 2019-04-29
EP3522880B1 (en) 2020-12-02
ES2859487T3 (es) 2021-10-04
RU2753607C2 (ru) 2021-08-18
WO2018067857A1 (en) 2018-04-12
PL3522880T3 (pl) 2021-08-23
PT3522880T (pt) 2021-02-22
RU2019111421A (ru) 2020-11-06

Similar Documents

Publication Publication Date Title
JOP20190056B1 (ar) مركبات للاستخدام في علاج القصور الكلوي الحاد
EA201790737A1 (ru) Комбинированная терапия
LT3672954T (lt) Junginiai, jų druskos ir jų naudojimas ligoms gydyti
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
MX385283B (es) Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control.
EP3720553C0 (en) PHOTOBIOMODULATION DEVICE FOR THE TREATMENT OF A RETINAL DISEASE
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
EP3448263A4 (en) Electrotherapeutic treatment
ZA201900343B (en) Self-contained treatment unit for haemodialysis treatments
MX388722B (es) Compuestos para tratar el cancer de ovario.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
EP3337828C0 (en) PCSK9 inhibitor antibodies for the treatment of hyperlipidemic patients undergoing lipoprotein apheresis
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
GEP20186939B (en) Medical treatments based on anamorelin
MX2017000306A (es) Metodos para tratar hipotension.
EP3411399A4 (en) TECHNOLOGY FOR ANTIBODY-ACTIVE SYNERGISM FOR THE TREATMENT OF DISEASES
EP3720509A4 (en) GENE THERAPY WITH A GLOBIN GENE FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EA201792123A1 (ru) Лечение боли
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
MX382608B (es) Tratamiento del prurito urémico.
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
IL282869A (en) Use of tivozanib to treat subjects with refractory cancer
IL283564A (en) Radiation-treated fibers, methods of treating and applications for use
EA201891008A3 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
IL262620A (en) Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury